Articles

The collaboration between Bristol Myers Squibb and Century Therapeutics will combine Century’s iPSC-derived allogeneic cell therapy platform with Bristol Myers Squibb’s expertise in cell therapy and oncology drug development.

Bristol Myers Squibb and Century Therapeutics to Collaborate on Developing iPSC-derived Allogeneic Cell Therapies

Fujifilm Diosynth Biotechnologies' 89,000 square-foot expansion of its BioProcess Innovation Center in Research Triangle Park, N.C., will double its capacity to support process characterization.

Fujifilm Grows Lab Space at North Carolina Facility

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

The Centers for Medicare and Medicaid Services took action to limit prescribing and use of Biogen’s new and controversial Alzheimer’s treatment Aduhelm (aducanumab).

Medicare Limits Aduhelm Coverage to Patients in Clinical Trials

The agreeement will add to Merck KGaA’s LNP and mRNA capabilities. 

Merck KGaA Acquires CDMO Exelead

The agreement expands Pfizer’s access to LNP formulation technology for mRNA vaccines and therapeutics.

Pfizer and Acuitas Therapeutics Collaborate on Lipid Nanoparticle Delivery System 

Bio-Rad’s new assays are designed to measure neutralizing antibodies against wild-type and significant variants of COVID-19.

Bio-Rad Introduces SARS-CoV-2 Variant Neutralization Antibody Assays

FDA granted Oncoloze’s OM-301 an orphan drug designation for the treatment of acute myeloid leukemia (AML).

FDA Grants Oncolyze Orphan Drug Designation for Leukemia Treatment

The collaboration will leverage Alynlam’s proprietary small interfering RNA (siRNA) technology to inhibit a target discovered by Novartis.

Novartis and Alnylam Announce Liver Therapy Collaboration

FDA amended it’s Emergency Use Authorization to shorten Moderna’s vaccine  booster dose interval from six to five months.

FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine

Neurimmune will receive up to $760 million for NI006, an investigational human monoclonal antibody in development for the treatment of transthyretin amyloid cardiomyopathy.

News